BR112012027143A8 - enzima da doença do armazenamento lisossomal - Google Patents

enzima da doença do armazenamento lisossomal

Info

Publication number
BR112012027143A8
BR112012027143A8 BR112012027143A BR112012027143A BR112012027143A8 BR 112012027143 A8 BR112012027143 A8 BR 112012027143A8 BR 112012027143 A BR112012027143 A BR 112012027143A BR 112012027143 A BR112012027143 A BR 112012027143A BR 112012027143 A8 BR112012027143 A8 BR 112012027143A8
Authority
BR
Brazil
Prior art keywords
storage disease
acid lipase
lysosomal storage
disease enzyme
lysosomal acid
Prior art date
Application number
BR112012027143A
Other languages
English (en)
Other versions
BR112012027143A2 (pt
BR112012027143B1 (pt
Inventor
J Harvey Alex
Quinn Anthony
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of BR112012027143A2 publication Critical patent/BR112012027143A2/pt
Publication of BR112012027143A8 publication Critical patent/BR112012027143A8/pt
Publication of BR112012027143B1 publication Critical patent/BR112012027143B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

enzima da doença do armazenamento lisossonal. a presente invenção refere-se a composições de lipase ácida lisossomal humana recombinante possuindo padrões de glicosilação específicos para internalização em células-alvo, um vetor contendo o ácido nucleio que condifica a lipase ácida lisossomal humana, uma célula hospedeira transformada com o vetor, composições farmacêuticas compreendendo a lipase ácida lisossomal humana recombinante e um método de tratamento de condições associadas com a deficiência de lipase ácida lisossomal.
BR112012027143-1A 2010-04-23 2011-04-23 Glicoproteínas de lipase ácida lisossomal recombinante humana isolada e composições farmacêuticas compreendendo as mesmas BR112012027143B1 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US34317710P 2010-04-23 2010-04-23
US61343177 2010-04-23
US39637610P 2010-05-26 2010-05-26
US61396376 2010-05-26
US40301110P 2010-09-09 2010-09-09
US61403011 2010-09-09
US45601410P 2010-10-29 2010-10-29
US61456014 2010-10-29
US201161432372P 2011-01-13 2011-01-13
US61432372 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme

Publications (3)

Publication Number Publication Date
BR112012027143A2 BR112012027143A2 (pt) 2016-11-16
BR112012027143A8 true BR112012027143A8 (pt) 2017-09-19
BR112012027143B1 BR112012027143B1 (pt) 2020-02-11

Family

ID=44834852

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027143-1A BR112012027143B1 (pt) 2010-04-23 2011-04-23 Glicoproteínas de lipase ácida lisossomal recombinante humana isolada e composições farmacêuticas compreendendo as mesmas

Country Status (21)

Country Link
US (4) US20130209436A1 (pt)
EP (3) EP3205351B1 (pt)
JP (4) JP5925187B2 (pt)
KR (1) KR101742346B1 (pt)
CN (2) CN105214076B (pt)
AU (1) AU2011242461B2 (pt)
BR (1) BR112012027143B1 (pt)
CA (2) CA2995446C (pt)
DK (2) DK2561069T3 (pt)
ES (2) ES2627535T3 (pt)
FI (1) FI3205351T3 (pt)
HK (2) HK1183059A1 (pt)
HU (2) HUE033217T2 (pt)
IL (2) IL222513A0 (pt)
LT (1) LT3205351T (pt)
MX (2) MX362430B (pt)
PL (2) PL3205351T3 (pt)
PT (2) PT2561069T (pt)
RU (2) RU2015151189A (pt)
SI (2) SI2561069T1 (pt)
WO (1) WO2011133960A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
US20080064862A1 (en) * 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP3205351B1 (en) 2010-04-23 2023-04-12 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
MX365007B (es) 2010-09-09 2019-05-20 Alexion Pharmaceuticals Inc Star Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
KR20140130443A (ko) * 2012-03-02 2014-11-10 시나게바 바이오파르마, 코포레이션 절두된 리소좀 산 리파제
EP3133932B1 (en) * 2014-04-23 2021-08-11 Alexion Pharmaceuticals, Inc. Egg white processing
US11235036B2 (en) 2016-06-17 2022-02-01 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
WO2018039163A1 (en) 2016-08-23 2018-03-01 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
WO2018064303A1 (en) 2016-09-30 2018-04-05 Alexion Pharmaceuticals, Inc. Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
WO2019152343A1 (en) 2018-02-01 2019-08-08 Alexion Pharmaceuticals, Inc. Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal
KR20220069917A (ko) * 2019-07-02 2022-05-27 엠6피 테라퓨틱스 (스위처랜드) 엘엘씨 리소좀 축적 장애의 치료를 위한 벡터 조성물 및 이의 사용 방법
CN114369620A (zh) * 2021-12-31 2022-04-19 广州辉园苑医药科技有限公司 一种可持续分泌lal的载体、脐带间充质干细胞及其构建方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) * 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996004001A1 (en) 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
DE69637875D1 (de) 1995-09-14 2009-04-30 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
CN1268741C (zh) 1996-09-13 2006-08-09 超卡里奥迪克治疗学股份有限公司 半乳糖苷酶a缺乏症的治疗
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
ES2268799T3 (es) 1997-10-29 2007-03-16 Genzyme Corporation Terapia genica para la enfermedad de gaucher.
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
PT1137762E (pt) 1998-12-07 2009-01-14 Genzyme Corp Tratamento da doença de pompe
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002036754A2 (en) 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6387680B1 (en) * 2001-03-29 2002-05-14 Pe Corporation (Ny) Isolated human lipase proteins, nucleic acid molecules encoding human lipase proteins, and uses thereof
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003064614A2 (en) 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
CA2482686C (en) 2002-04-16 2012-04-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A marker for measuring liver cirrhosis
CA2499188A1 (en) 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
EP1784203B1 (en) 2004-08-19 2010-06-30 Biogen Idec MA Inc. Refolding transforming growth factor beta family proteins
US20080064862A1 (en) 2004-12-29 2008-03-13 Avigenics, Inc. Transgene expression in a avians
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
CA2622074C (en) 2005-10-05 2013-01-22 Avigenics, Inc. Rapid production of high titer virus
CN101291684A (zh) 2005-10-21 2008-10-22 阿维季尼克斯股份有限公司 甘醇化和糖基化的禽类来源的治疗性蛋白
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
EP2037945A4 (en) 2006-05-24 2012-07-04 Myelin Repair Foundation Inc PERMEABILITY OF THE HEMATO-ENCEPHALIC BARRIER
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
WO2008131431A2 (en) 2007-04-23 2008-10-30 St. Louis University Modulation of blood brain barrier protein expression
US8956825B2 (en) 2007-05-24 2015-02-17 The United States Of America As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
NZ599928A (en) 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of asthma
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009032171A1 (en) 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
JP5571576B2 (ja) 2008-01-07 2014-08-13 シナジェバ・バイオファーマ・コーポレイション トリにおけるグリコシル化
WO2010033854A2 (en) 2008-09-19 2010-03-25 Synageva Biopharma Corp. Avian derived fusion proteins
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
PL2995306T4 (pl) 2009-10-19 2019-07-31 Amicus Therapeutics, Inc. Nowe kompozycje do zapobiegania i/lub leczenia lizosomalnych zaburzeń spichrzeniowych
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP3205351B1 (en) * 2010-04-23 2023-04-12 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
US20150030582A1 (en) * 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
MX365007B (es) 2010-09-09 2019-05-20 Alexion Pharmaceuticals Inc Star Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
CN103492574B (zh) 2011-02-22 2015-12-09 加州理工学院 使用腺相关病毒（aav）载体递送蛋白
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
EP2721151B1 (en) 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
CN103842517A (zh) 2011-08-03 2014-06-04 莲花组织修复公司 胶原蛋白7及相关方法

Also Published As

Publication number Publication date
CA2796607A1 (en) 2011-10-27
US10407671B2 (en) 2019-09-10
JP6496690B2 (ja) 2019-04-03
CA2796607C (en) 2019-09-10
JP2013526856A (ja) 2013-06-27
EP4241854A3 (en) 2023-11-08
SI3205351T1 (sl) 2023-09-29
JP6212081B2 (ja) 2017-10-11
PL2561069T3 (pl) 2017-08-31
US20130209436A1 (en) 2013-08-15
DK3205351T3 (da) 2023-06-19
WO2011133960A2 (en) 2011-10-27
AU2011242461A1 (en) 2012-11-15
JP2018100289A (ja) 2018-06-28
MX338426B (es) 2016-04-15
HK1183059A1 (en) 2013-12-13
JP5925187B2 (ja) 2016-05-25
CA2995446A1 (en) 2011-10-27
RU2015151189A (ru) 2019-01-14
CN105214076B (zh) 2020-03-31
EP2561069A4 (en) 2014-03-26
RU2741116C2 (ru) 2021-01-22
CN105214076A (zh) 2016-01-06
RU2017105260A3 (pt) 2020-06-15
US20170314000A1 (en) 2017-11-02
EP4241854A2 (en) 2023-09-13
BR112012027143A2 (pt) 2016-11-16
EP3205351A1 (en) 2017-08-16
FI3205351T3 (fi) 2023-07-06
MX2012012356A (es) 2013-04-11
BR112012027143B1 (pt) 2020-02-11
EP2561069A2 (en) 2013-02-27
HK1219655A1 (zh) 2017-04-13
CA2995446C (en) 2020-05-12
AU2011242461B2 (en) 2015-10-01
IL252115A0 (en) 2017-07-31
LT3205351T (lt) 2023-07-25
CN102985538B (zh) 2015-09-09
DK2561069T3 (en) 2017-05-01
EP2561069B1 (en) 2017-03-08
KR20130113312A (ko) 2013-10-15
IL252115B (en) 2019-11-28
WO2011133960A3 (en) 2012-07-12
CN102985538A (zh) 2013-03-20
PT3205351T (pt) 2023-06-28
EP3205351B1 (en) 2023-04-12
RU2012149936A (ru) 2014-05-27
IL222513A0 (en) 2012-12-31
HUE062163T2 (hu) 2023-09-28
PT2561069T (pt) 2017-05-22
US10858638B2 (en) 2020-12-08
PL3205351T3 (pl) 2023-08-28
US20200063113A1 (en) 2020-02-27
JP2016190867A (ja) 2016-11-10
ES2950358T3 (es) 2023-10-09
ES2627535T3 (es) 2017-07-28
RU2017105260A (ru) 2018-08-17
SI2561069T1 (sl) 2017-07-31
HUE033217T2 (hu) 2017-11-28
JP2015204842A (ja) 2015-11-19
US11560554B2 (en) 2023-01-24
US20210171922A1 (en) 2021-06-10
KR101742346B1 (ko) 2017-06-15
MX362430B (es) 2019-01-17
WO2011133960A9 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
BR112012027143A2 (pt) enzima da doença do armazenamento lisossomal
NI201300083A (es) Inhibidores de glucosilceramida sintasa
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
BR112014027227A2 (pt) modificação alvejada de malato desidrogenase
BRPI0910457A2 (pt) variante de fitase, ácido nucléico, vetor, célula hospedeira, método de produção de uma variante de fitase, composição enzimática, usos, método para a produção de um alimento ou ração para animal e respectivos alimento ou composição de ração para animal e método de redução dos níveis de redução de fósforo em estrume animal
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
MX2019010226A (es) Composiciones de nanoparticulas lipidicas y metodos para administracion de arnm.
BR112013027963A2 (pt) "variante de subtilisina com atividade proteolítica, ácido nucleico, vetor de expressão, célula hospedeira, composição e método de limpeza".
BR112013010551A8 (pt) variantes de isopreno sintase para produção aprimorada de isopreno
BR112012033214A2 (pt) método e composições para distribuição no snc de iduronato-2-sulfatase
BR112012020277A2 (pt) "enzimas celulase otimizadas".
BRPI0911511B8 (pt) formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
BR112015009201A2 (pt) composição compreendeendo um polipeptídeo recombinante, ácido nucleico codificando o mesmo, célula hospedeira, bem como métodos para produzir uma beta-glucosidase e para hidrolisar um substrato de biomassa lignocelulósica
BR112015005782A2 (pt) variantes de enzima com propriedades aprimoradas de éster-sintase
WO2012145729A3 (en) Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity
BR112013003471A2 (pt) solução de testosterona, e, método para tratar deficiência de testosterona
BR112014010053A2 (pt) variantes de isopreno sintase com solubilidade aprimorada para produção de isopreno
BRPI0908567A2 (pt) sequência de ácido nucleico, proteína, método para a produção de ácido itacônico em um microorganismo, célula hospedeira, usos de uma proteína e da combinação de proteína com a enzima cad e/ou uma proteína trasportadora de di/tricarboxilato da mitocôndria
BRPI1014942A2 (pt) "polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
BR112015004965A2 (pt) silenciamento de gene transcricional de endogenes em plantas
BR112015024118A2 (pt) protease aspártica vegetal, método de tratamento médico, utilização de uma protease aspártica vegetal, método cosmético para melhorar o aspeto da pele, protease aspártica vegetal cardosina isolada, composição, método para produzir uma protease aspártica vegetal, vetor, célula, célula com um genoma modificado, método de promover a acumulação de um polipeptídeo de interesse no vacúolo de uma célula, e, ácido nucleico
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
BRPI1007269A2 (pt) métodos para produzir um polipeptídeo, polipeptídeo, dna, cassete de expressão, célula hospedeira não humana, organismo transformado, métodos para reconhecer seletivamente um par de bases em uma sequência de dna, e para modular expressão de um gene alvo em uma célula, vetor, e , método para produzir um dna.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA LLC (US)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMACEUTICALS, INC. (US)